Is Ascelia Pharma (STO:ACE) Using Too Much Debt?
Jul 22
ACE Share Price Performance
SEK 4.69
2.54 (118.41%)
Price SEK 4.69
Share PriceSEK 4.69
ACE Community Narratives
There are no narratives available yet.
Ascelia Pharma AB (publ) Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 05, 2025
- Earnings per share (EPS)
- -0.82
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 7.4%
Ascelia Pharma AB (publ) Competitors
Snowflake Analysis
About ACE
- Founded
- 1999
- Employees
- 11
- CEO
- WebsiteView website
Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden.
Market Insight
Market sentiment on BTC treasury companies is moving, and with volatility rising, disagreements over their future prospects are as heated as ever.
Continue reading
Swedish Market Performance
- 7 Days: 1.9%
- 3 Months: 4.2%
- 1 Year: -0.3%
- Year to Date: 2.8%
The market is up 1.9% in the last 7 days, led by the Industrials and all sectors gaining ground. In the last 12 months, the market has been flat. As for the next few years, earnings are expected to grow by 17% per annum. Market details ›